Literature DB >> 21416694

Pyrazinamide plasma concentrations in young children with tuberculosis.

Helen McIlleron1, Marianne Willemse, Hendrik Simon Schaaf, Peter John Smith, Peter Roderick Donald.   

Abstract

Pyrazinamide plasma concentrations were determined in 34 children (median age, 3.32 years) 1 month after commencing antituberculosis treatment. The median (interquartile range) peak concentration was 30.7 (25.5, 35.0) mg/L after a median dose of 23 mg/kg. Peak concentrations < 20 mg/L were found in 5 children (15%) and such low concentrations were particularly likely after doses < 20 mg/kg.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21416694     DOI： 10.1097/inf.0b013e3181fbefe1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  7 in total

1.  Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Authors:  Museveni Justine; Anita Yeconia; Ingi Nicodemu; Domitila Augustino; Jean Gratz; Estomih Mduma; Scott K Heysell; Sokoine Kivuyo; Sayoki Mfinanga; Charles A Peloquin; Theodore Zagurski; Gibson S Kibiki; Blandina Mmbaga; Eric R Houpt; Tania A Thomas
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

Review 2.  A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.

Authors:  Kyle John Wilby; Sara Shabana; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 3.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

4.  Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Authors:  Simbarashe P Zvada; Paolo Denti; Peter R Donald; H Simon Schaaf; Stephanie Thee; James A Seddon; Heiner I Seifart; Peter J Smith; Helen M McIlleron; Ulrika S H Simonsson
Journal:  J Antimicrob Chemother       Date:  2014-01-31       Impact factor: 5.790

5.  Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.

Authors:  Aparna Mukherjee; Thirumurthy Velpandian; Mohit Singla; Kunwar Kanhiya; Sushil K Kabra; Rakesh Lodha
Journal:  BMC Infect Dis       Date:  2015-03-14       Impact factor: 3.090

6.  Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.

Authors:  R Mlotha; D Waterhouse; F Dzinjalamala; A Ardrey; E Molyneux; G R Davies; S Ward
Journal:  J Antimicrob Chemother       Date:  2015-03-10       Impact factor: 5.790

7.  EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa.

Authors:  George M Miiro; Odile Ouwe Missi Oukem-Boyer; Ousmane Sarr; Maerangis Rahmani; Francine Ntoumi; Keertan Dheda; Alexander Pym; Souleymane Mboup; Pontiano Kaleebu
Journal:  BMC Public Health       Date:  2013-03-22       Impact factor: 3.295
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.